Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NC-NDJournal of gastrointestinal oncology

Treatment completion, symptom response, and survival after palliative liver-directed radiotherapy: a retrospective cohort study.

  • Abdulmoid Asif1
  • Abdulmoiz Asif1
  • Michael K Rooney2
  • Ahmed O Kaseb3
  • Sunyoung S Lee3
  • Zeyad A Metwalli4
  • Bruno C Odisio4
  • Joshua D Kuban4
  • Vincent Bernard Pagan1
  • Prajnan Das1
  • Emma B Holiday1
  • Sonal S Noticewala1
5 more authors
  • Grace L Smith1
  • Albert C Koong1
  • Ethan B Ludmir1
  • Eugene J Koay1
  • Enoch Chang1
4 affiliations
  1. 1Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  2. 2Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  3. 3Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  4. 4Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Read full textPDFDOICite

Abstract

Prior studies have shown that palliative liver-directed radiotherapy alleviates pain in patients with hepatocellular carcinoma (HCC) and liver metastases. These findings highlight the need to identify factors associated with treatment completion and survival. We evaluated factors associated with outcomes in patients receiving palliative liver-directed radiotherapy. We retrospectively analyzed 42 patients with HCC, intrahepatic cholangiocarcinoma, or liver metastases who received palliative radiotherapy at our institution between 2013 and 2024. A query of all patients in the electronic health record who received liver-directed palliative radiotherapy for these tumor types was conducted to find eligible patients. Baseline characteristics, laboratory values, and treatment details were collected. Baseline laboratory tests were taken within 48 h before the start of radiotherapy. The primary objective was to evaluate safety (acute and late adverse events) and efficacy (patient-reported pain response, bleeding stabilization, consolidative treatment response, and thrombus control). Adverse events were defined as any radiotherapy-related complications. Factors associated with survival and treatment completion were evaluated. The dose and fractionation of the radiotherapy regimens included: 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Treatment completion was defined as completion of the prescribed radiotherapy dose and fractionation, and follow-up was conducted by the clinical team, including medical and radiation oncologists. Twenty-eight (67%) patients had pain at baseline. Among 25 evaluable patients, pain improved in 17 (68%) within 1 month after receiving radiotherapy. Among 18 evaluable patients at 1-3 months after receiving radiotherapy, pain improved in 11 (61%) and was stable in 5 (28%). The acute grade 3 adverse event rate was 5%, with no acute grade 4+ adverse events or any late adverse events observed. The median overall survival was 3 months [95% confidence interval (CI): 1.73-10.30], and the median follow-up time was 1.8 months. A higher baseline albumin-bilirubin (ALBI) score was associated with shorter overall survival (hazard ratio 3.65, 95% CI: 1.83-7.28; P<0.001) and greater likelihood of not completing the prescribed radiotherapy course (odds ratio 4.36, 95% CI: 1.19-27.44; P=0.02). Six patients did not complete palliative radiation treatment due to clinical decline (n=3) or worsening liver function (n=3). Thirty-one deaths were documented during follow-up. Palliative liver-directed radiotherapy was well tolerated and associated with early pain improvement across different tumor histologies. Baseline clinical factors, along with ALBI score, may be associated with survival and treatment completion.

Related

  1. Hemostatic Response to Palliative Radiotherapy for Bleeding Gastric Cancer and Pretreatment Endoscopic Characteristics: A Retrospective Cohort Study
    Kazuya Kimura, Kenta Watanabe, Yuki Wada +9
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  2. ASSESSMENT OF TREATMENT RESPONSE RESPONSE AND THE ROLE OF COMPLETION SURGERY AFTER CONCURRENT CRTAND BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP
    Camille Mimoun, Xavier Carcopino, Lobna Ouldamer +40
    Journal of Gynecology Obstetrics and Human ReproductionPeer-reviewedCC BYFull textGeneral biologyOncologyHAL
  3. Treatment Completion and Associated Factors in Drug-Resistant Tuberculosis, Mbuji-Mayi, Democratic Republic of the Congo: A Retrospective Cohort Study.
    Elvis Badianga Kumbu, Simon Ilunga Kandolo, Michel Kabamba Nzaji
    Infection and drug resistancePeer-reviewedCC BY-NCFull textInfectious diseaseEurope PMC
  4. Surgical treatment of osteoradionecrosis of the jaw following radiotherapy for oropharyngeal cancer: A retrospective clinical analysis in a single-center.
    Yu Nakai, Ken-Ichiro Sakata, Kazuhito Yoshikawa +7
    Journal of dental sciencesPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Factors Influencing the Treatment Response of Tetracyclines for Papulopustular Rash Induced by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Study.
    Tae Min Kim, Namkyu Kim, Jimin Woo +3
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{asif2026treatment,
  title = {{Treatment completion, symptom response, and survival after palliative liver-directed radiotherapy: a retrospective cohort study.}},
  author = {Abdulmoid Asif and Abdulmoiz Asif and Michael K Rooney and Ahmed O Kaseb and Sunyoung S Lee and Zeyad A Metwalli and Bruno C Odisio and Joshua D Kuban and Vincent Bernard Pagan and Prajnan Das and Emma B Holiday and Sonal S Noticewala and Grace L Smith and Albert C Koong and Ethan B Ludmir and Eugene J Koay and Enoch Chang},
  journal = {Journal of gastrointestinal oncology},
  year = {2026},
  month = oct,
  doi = {10.21037/jgo-2026-0593},
  url = {https://europepmc.org/article/MED/42996886},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Treatment completion, symptom response, and survival after palliative liver-directed radiotherapy: a retrospective cohort study.
AU  - Abdulmoid Asif
AU  - Abdulmoiz Asif
AU  - Michael K Rooney
AU  - Ahmed O Kaseb
AU  - Sunyoung S Lee
AU  - Zeyad A Metwalli
AU  - Bruno C Odisio
AU  - Joshua D Kuban
AU  - Vincent Bernard Pagan
AU  - Prajnan Das
AU  - Emma B Holiday
AU  - Sonal S Noticewala
AU  - Grace L Smith
AU  - Albert C Koong
AU  - Ethan B Ludmir
AU  - Eugene J Koay
AU  - Enoch Chang
PY  - 2026
DA  - 2026/10/23
JO  - Journal of gastrointestinal oncology
DO  - 10.21037/jgo-2026-0593
UR  - https://europepmc.org/article/MED/42996886
AB  - Prior studies have shown that palliative liver-directed radiotherapy alleviates pain in patients with hepatocellular carcinoma (HCC) and liver metastases. These findings highlight the need to identify factors associated with treatment completion and survival. We evaluated factors associated with outcomes in patients receiving palliative liver-directed radiotherapy. We retrospectively analyzed 42 patients with HCC, intrahepatic cholangiocarcinoma, or liver metastases who received palliative radiotherapy at our institution between 2013 and 2024. A query of all patients in the electronic health record who received liver-directed palliative radiotherapy for these tumor types was conducted to find eligible patients. Baseline characteristics, laboratory values, and treatment details were collected. Baseline laboratory tests were taken within 48 h before the start of radiotherapy. The primary objective was to evaluate safety (acute and late adverse events) and efficacy (patient-reported pain response, bleeding stabilization, consolidative treatment response, and thrombus control). Adverse events were defined as any radiotherapy-related complications. Factors associated with survival and treatment completion were evaluated. The dose and fractionation of the radiotherapy regimens included: 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Treatment completion was defined as completion of the prescribed radiotherapy dose and fractionation, and follow-up was conducted by the clinical team, including medical and radiation oncologists. Twenty-eight (67%) patients had pain at baseline. Among 25 evaluable patients, pain improved in 17 (68%) within 1 month after receiving radiotherapy. Among 18 evaluable patients at 1-3 months after receiving radiotherapy, pain improved in 11 (61%) and was stable in 5 (28%). The acute grade 3 adverse event rate was 5%, with no acute grade 4+ adverse events or any late adverse events observed. The median overall survival was 3 months [95% confidence interval (CI): 1.73-10.30], and the median follow-up time was 1.8 months. A higher baseline albumin-bilirubin (ALBI) score was associated with shorter overall survival (hazard ratio 3.65, 95% CI: 1.83-7.28; P<0.001) and greater likelihood of not completing the prescribed radiotherapy course (odds ratio 4.36, 95% CI: 1.19-27.44; P=0.02). Six patients did not complete palliative radiation treatment due to clinical decline (n=3) or worsening liver function (n=3). Thirty-one deaths were documented during follow-up. Palliative liver-directed radiotherapy was well tolerated and associated with early pain improvement across different tumor histologies. Baseline clinical factors, along with ALBI score, may be associated with survival and treatment completion.
SN  - 2078-6891
SN  - 2219-679X
ER  -